Siemens Fonds Invest GmbH Has $43,000 Position in Pfizer Inc. (NYSE:PFE)

Siemens Fonds Invest GmbH reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 99.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,625 shares of the biopharmaceutical company's stock after selling 214,932 shares during the period. Siemens Fonds Invest GmbH's holdings in Pfizer were worth $43,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mcdonald Partners LLC boosted its stake in Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock valued at $2,926,000 after acquiring an additional 9,963 shares during the period. Bank of Jackson Hole Trust acquired a new position in shares of Pfizer during the fourth quarter worth approximately $264,000. Harvey Capital Management Inc. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $544,000. ING Groep NV boosted its position in shares of Pfizer by 48.6% during the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock worth $26,881,000 after buying an additional 331,403 shares during the period. Finally, WCM Investment Management LLC boosted its position in shares of Pfizer by 128.7% during the fourth quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company's stock worth $3,062,000 after buying an additional 65,238 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.01 during trading on Friday, hitting $23.46. The company had a trading volume of 56,576,195 shares, compared to its average volume of 41,090,161. The company has a market cap of $133.38 billion, a P/E ratio of 16.64, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business's 50-day moving average is $23.12 and its 200 day moving average is $25.06. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.33%. Pfizer's dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.